Since recruitment for the MaGiCAD study was completed in 2005, a number of changes have occurred within the management of the study, which has led to a delay in the analysis of the samples and data that we obtained. However, I am pleased to announce that the tripartate arrangement between the University of Cambridge, Papworth Hospital and TCP Innovations that funded and ran the study during its active recruiting phase has now been replaced by a single new Sponsor, Total Scientific Ltd.

Total Scientific Ltd. are a small biotechnology-focussed company based on the Babraham Research Campus. Total Scientific (a subsidiary company of TCP Innovations) is run by Dr. David Grainger and Dr. David Mosedale, two of the original founders of the MaGiCAD study, ensuring continuity with the previous management. In the last twelve months we have performed comprehensive NMR metabolomics analysis of all of the MaGiCAD samples, as originally planned, and have recently (as of May 2013) obtained all of the five-year follow-up data that will now enable us to complete the originally planned analyses.

The purpose of the website is to provide up-to-date information about the study, and the results we are generating, accessible to those who participated, as well as the wider community.

For more in-depth information on the MaGiCAD study, please see the research section which provides information for other scientific and medical professionals. Importantly, as the primary purposes for which the MaGiCAD study was set up have now been completed, we strongly encourage other research professionals to contact us and talk to us about accessing the MaGiCAD study for use in their own work. Such research must fit within the confines of the Ethical Approval granted to the original study, which is to investigate biomarkers and diagnosis of human diseases. Of course, primarily the cohort was designed to be a resource for diagnosis of coronary heart disease, but with five-year follow-up now completed it is clear that a large number of the participants were suffering from other diseases, such as a variety of cancers. Five-year follow-up on large cohort-based studies such as this is rare, and we welcome the opportunity to help with the diagnosis and treatment of all human diseases using the MaGiCAD study samples and data. Please click here to request further information.

Please note that recruitment to MaGiCAD is now closed, and it is not possible to volunteer for participation. A further study with a similar design, called PUMA, which ran at several hospitals across the UK has also now completed recruitment. Together, MaGiCAD and PUMA represent a unique resource for evaluating new diagnostic tests for heart disease and we hope to report our exciting findings shortly. The website for the PUMA study has now been combined into that of the MaGiCAD study, re-inforcing the links between these two studies. For more information on the PUMA study, please click here.